Methods of treating an overweight or obese subject

Abstract

The disclosure herein generally relates to methods of treating an overweight or obese condition, and overweight or obesity-related conditions. In one embodiment, the disclosure provides a method of treating an overweight or obese condition involving administering to the subject in need thereof, an amount of a pharmaceutical composition including a MetAp-2 inhibitory compound, or a salt, ester, or prodrug thereof, effective to result in weight loss in the subject.

What is claimed is: 
     
       1. A method of treating a subject having an overweight or obese condition, the method comprising: administering to the subject in need thereof, a therapeutically effective amount of a pharmaceutical composition comprising a compound of Formula C-D wherein C is represented by: 
       
         
           
           
               
               
           
         
       
       and D is represented by: 
       
         
           
           
               
               
           
         
       
       wherein:
 Z, R and Y are not present; 
 X is C 1-6 alkyl; 
 P is a moiety selected from the group consisting of: 
 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
       2. A method of treating a subject having an overweight or obese condition, the method comprising: administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a compound selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
       and a pharmaceutically acceptable salt thereof. 
     
     
       3. The method of  claim 2 , wherein the subject has a Body Mass Index measurement selected from the group consisting of: at least about 25 kg/m 2 , at least about 30 kg/m 2 , and at least about 40 kg/m 2 . 
     
     
       4. The method of  claim 2 , wherein the pharmaceutical composition is administered non-parenterally. 
     
     
       5. The method of  claim 2 , wherein the pharmaceutical composition is administered parenterally. 
     
     
       6. The method of  claim 2 , wherein the pharmaceutical composition is administered subcutaneously. 
     
     
       7. A method for controlling hepatic steatosis in an obese subject being treated for obesity, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
       and a pharmaceutically acceptable salt thereof.